Comapany Overview

A Leader in global Industrial Biotechnology



Yong Chul, Shin (Chenny)
CEO at AMICOGEN, Inc.

" Thank you for your continual trust and interest in Amicogen.

Started as a college venture company in 2000, Amicogen is Korea's leading industrial biotechnology company realizing the value of contributing to human health and environmental protection. " 


We trade
with vision

Curabitur dictum tincidunt aliquam. Pellentesque quis magna at tortor vestibulum interdum.
Nulla maximus imperdiet libero ac tincidunt. In laoreet porta dui et accumsan. Suspendisse bibendum metus diam, eu placerat nisi vulputate at.

Donec ullamcorper volutpat lorem, ac molestie arcu ultricies eu. In vitae blandit arcu, vel sagittis nisi. Nullam vel rhoncus tellus. Vestibulum commodo nisl id ipsum consequat auctor. Quisque auctor tincidunt diam ac accumsan. Praesent orci ante, pellentesque id sapien eget, semper ullamcorper tortor.

Innovative,
interoperable platform


Trading Value

$100m

Curabitur volutpat, velit quis dictum viverra, ante nulla ultrices augue, ac pellentesque magna sapien et nisi. Suspendisse posuere ultrices hendrerit.


Trading Value

200+

Curabitur volutpat, velit quis dictum viverra, ante nulla ultrices augue, ac pellentesque magna sapien et nisi. Suspendisse posuere ultrices hendrerit.


Trading Value

10+

Curabitur volutpat, velit quis dictum viverra, ante nulla ultrices augue, ac pellentesque magna sapien et nisi. Suspendisse posuere ultrices hendrerit.

In luctus sollicitudin cursus. Nullam efficitur porttitor blandit. Phasellus quis posuere eros.

Pellentesque semper venenatis nibh, et rhoncus tortor sagittis nec. Donec posuere convallis ultricies. Curabitur in ex nulla. Curabitur at urna commodo, consectetur dui ut, pulvinar urna. Vivamus convallis gravida erat et faucibus. Aenean urna magna, consequat non mattis sit amet, aliquet ut tortor. Mauris euismod et turpis sed porttitor. Integer cursus nulla vitae risus sollicitudin, non accumsan ipsum dapibus. Mauris non mattis sapien. Proin vitae mi condimentum orci scelerisque facilisis vel ut metus. Donec nibh dui, imperdiet sit amet augue at.

Donec lobortis aliquet dui, sit amet tempor felis posuere et. Donec ac quam eu arcu suscipit aliquam.
Nam vestibulum justo in mauris ullamcorper, id elementum est congue. Phasellus lorem erat, iaculis ac arcu non, dapibus convallis ex. Mauris nibh lacus, bibendum eu elit sit amet, tempus scelerisque nisi.

*Nulla a lorem mollis, imperdiet lorem sed, mollis mi.

*Sed malesuada dictum mauris quis venenatis. Ut consequat odio ac mauris feugiat pellentesque eget ut quam.

*Nulla a lorem mollis, imperdiet lorem sed, mollis mi.


Biotechnology company leading the health of humankind and the sustainability of the 

global environment

Amicogen is leading biopharmaceutical, pharmaceutical, food, cosmetic and other industrial specialty enzyme and protein by utilizing our source technologies, such as directed gene evolution and protein engineering. Special pharmaceutical enzyme, which is our key product, is a core material that replaces the chemical process with the enzyme (biocatalyst) process, an eco-friendly production method. Compared to chemical processes, biocatalyst processes can reduce wastewater, waste, and CO ₂ emissions. As it can simplify production processes and increase productivity, it is highly attracted as a 21st century future growth technology that will replace conventional methods.



Global bio company


Amicogen has equipped with a strategic business structure in 3 business divisions, 'Enzyme · bio pharmaceuticals’, 'health care' and 'bio process/ CDMO by combining sustainable enzyme technology and its applied technology.

The 'Enzyme · bio pharmaceuticals’ business has concentrated on the Green API business (eco-friendly raw material pharmaceutical production method) such as special enzymes and DX project and has led the development of eco-friendly technology in the global pharmaceutical market. In addition, in cooperation with global life science companies, we are promoting the endolysin business, a therapeutic agent for antibiotic-resistant mutant bacteria (super bacteria). By commercializing endolysin, the so-called the next-generation antibiotics, we desire to contribute to human health greatly by replacing conventional chemical antibiotics and by solving the problem of antibiotic resistance.

The 'health care business’ develops and sells health functional food materials and finished products such as collagen (tree) peptide, pinitol/ DCI, N-acetylglucosamine, and health food enzyme by utilizing enzyme technologies (B2B, B2C). The 'bio process/ CDMO business' has focused on the chromatography resin and medium business, which are essential for the biopharmaceutical production.

Amicogen has global level capability and organization from R&D to process development, quality control, clinical, production, sales and marketing. Based on the biotech technology and know-how for more than 20 years and the solid partnership with partner companies in Korea and abroad, we will leap forward to become a global biotechnology company.



Amicogen has been constantly challenging the development of technologies in fields which no one attempt for the past 20 years.
We did our best for technical innovation with the belief that we will challenge and succeed if the world needs it even if it takes a long time and someone must do it. We promise that Amicogen will continue to strive for making a bigger leap forward and will fulfill our social responsibility and role for the global environment and for a better life of humankind.



Shin Yong Chul, CEO, Amicogen

Environmental

Social

Governance

Management



Amicogen believes the preservation of environment and better life of human being are valuable.
We are contribution social responsibility in various fields.